Adenuric® (febuxostat): Risk of hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock
2012.05.22
Active substance: febuxostat
Serious hypersensitivity reactions have been reported under treatment with Adenuric®. In most of the cases these reactions occurred during the first month of treatment with febuxostat.Treatment should be discontinued immediately if signs or symptoms of a serious hypersensitivity reaction occur.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN